Diisocyanate-induced asthma in Switzerland: long-term course and patients’ self-assessment after a 12-year follow-up by Martin Rüegger et al.
Rüegger et al. Journal of Occupational Medicine and Toxicology 2014, 9:21
http://www.occup-med.com/content/9/1/21RESEARCH Open AccessDiisocyanate-induced asthma in Switzerland:
long-term course and patients’ self-assessment
after a 12-year follow-up
Martin Rüegger, Doreen Droste, Markus Hofmann, Marcel Jost and David Miedinger*Abstract
Background: Isocyanates are among the most common causes of occupational asthma (OA) in Switzerland. Patients
with OA have been shown to have unfavourable medical, socioeconomic and psychological outcomes. We
investigated long-term asthma and the socio-economic outcomes of diisocyanate-induced asthma (DIA) in
Switzerland.
Patients and methods: We conducted an observational study on 49 patients with DIA and followed 35 of these
patients over a mean exposure-free interval of 12 ± 0.5 (range 11.0-13.0) years. At the initial and follow-up examinations,
we recorded data on respiratory symptoms and asthma medication; measured the lung function; and tested for
bronchial hyperreactivity. We allowed the patients to assess their state of health and overall satisfaction using a
visual analogue scale (VAS) at these visits.
Results: The 35 patients whom we could follow had a median symptomatic exposure time of 12 months, interquartile
range (IQR) 26 months and a median overall exposure time of 51 (IQR 104) months. Their subjective symptoms
(p < 0.001) and the use of asthma medication (p = 0.002), particularly the use of inhaled corticosteroids (p < 0.001),
decreased by nearly 50%. At the same time, the self-assessment of the patients’ state of health and overall satisfaction
increased considerably according to both symptomatology and income. In contrast, slight reductions in terms of FVC%
predicted from 102% to 96% (p = 0.04), of FEV1% predicted from 91% to 87% (p = 0.06) and of the FEV1/FVC ratio of
3%; (p = 0.01) were observed while NSBHR positivity did not change significantly. In univariate as well as multivariate
logistic analyses we showed significant associations between age, duration of exposure and FEV1/FVC ratio with
persistent asthma symptoms and NSBHR.
Conclusions: We found that the patients’ symptoms, the extent of their therapy and the decrease in their lung
volumes during the follow-up period were similar to the findings in the literature. The same hold true for some
prognostic factors, whereas the patients’ self-assessment of their state of health and overall satisfaction improved
considerably.
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For more than two decades diisocyanates, a group of
highly reactive and widely used chemicals, were one of
the most common causes of occupational asthma in
industrialised countries [1] though the incidence of
diisocyanate induced occupational asthma (DIA) seems
to have decreased over recent years [2-4].* Correspondence: david.miedinger@suva.ch
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have shown a poor outcome for DIA even in the absence
of additional exposure to the offending agent. Approxi-
mately 50-82% of persons who suffer from DIA do not
recover completely and need continuous anti-asthmatic
therapy [5-8]. According to the literature, recovery depends
on a series of prognostic factors, such as the lung volume
at the beginning of exposure [9], the time of diagno-
sis [10,11], the degree of bronchial hyperreactivity [9],
the length of exposure time [12,13], the duration ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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of follow-up [16,17].
Until the early 1990s, there were only clinical follow-
up studies on DIA that explored short time periods
[7,8,12,13,18]. Therefore, we decided to do a long-term
study with our own DIA patients beginning in 1993 and
covering a time period of at least 10 years. Subsequently,
in 2000 and in 2003, two carefully conducted studies on
the outcome of patients with DIA over a 12-year follow-up
were published [19,20].
The aim of our study was to investigate the long-term
outcome of DIA in a non-preselected group of patients;
we focussed on asthma symptoms, the need for treatment,
changes in lung function and on nonspecific bronchial
hyperreactivity (NSBHR). Further we wanted to evaluate
the factors that were associated with persistent asthma
symptoms and NSBHR [16] as well as the individual
state of health and overall satisfaction at follow-up.
Materials and methods
All patients with suspected DIA reported to Suva (Swiss
Accident Insurance Fund) between 1993 and 1995 were
eligible for the study. Patients were included if the com-
bination of their history and their spirometric findings,
peak expiratory flow (PEF) recordings or inhalation chal-
lenge test results confirmed the diagnosis [21]. All of the
patients gave their informed consent to participate in the
study.
The patients who were admitted to our study had been
exposed to one or more of the following diisocyanates:
toluene diisocyanate (TDI), diphenylmethane diisocyanate
(MDI), hexamethylene diisocyanate (HDI), naphthylene
diisocyanate (NDI) or isophorone diisocyanate (IPDI) or
one of their reactive prepolymers either continuously or
intermittently.
We performed an uncontrolled observational study
over 12 years. For each subject, a detailed clinical and
occupational history was recorded and lung function
and bronchoprovocation tests were performed between
1993 and 1995, i.e., at the time of diagnosis (T0), and
again in 2006, at the time of re-evaluation (T1). The
participants’ longitudinal results are presented with data
available at T0 and T1.
The data were recorded by one of Suva’s occupational
physicians at three different locations (Lausanne, Lucerne
and Winterthur) during 1993–1995 (T0) and again in
2006 (T1) by DD as part of her doctoral thesis except two
patients who were interviewed and examined by MH, and
two others by their family doctors because of the patients’
limited mobility. To ensure uniformity of questioning a
checklist was used that had been established before. Most
of the data have been collected routinely when evaluating
notified cases in order to determine causality of occupa-
tional asthma (OA).The subject’s history included upper airway symptoms,
such as nasal flow and itching, and lower airway symp-
toms, such as irritation, cough, wheezing, dyspnoea,
chest tightness, and their temporal relationship to work.
Additionally, information on the use of asthma medica-
tions, smoking habits, isocyanate exposure and current
workplace as well as socioeconomic aspects were gathered.
In 2006, the subjects were asked to report their state
of health as well as their overall satisfaction using two
identical 10 cm neutral VASs. These measures reflect
subjective factors in a global manner but correlate highly
with several standard questionnaires and are accurate
and useful for assessing symptoms, such as pain, anxiety
and psychological distress [22]. Patients had to enter one
mark retrospectively for the time T0 and another mark
for the current time, T1. The second VAS mark could
not be set until the first one was covered. The left end of
the scale (0 cm) signified the worst rating conceivable,
whereas the right end (10 cm) indicated the optimal rating.
Between 1993 and 1995, all patients had a walk-through
visit by an occupational physician to confirm exposure to
isocyanates and to exclude relevant co-exposure to other
sensitizers or irritants that might have caused the reported
symptoms (results not reported).
All of the patients underwent routine clinical exami-
nations as well as standard lung function tests at one
of Suva’s three occupational medical centres. The tests
conducted at time T0 and T1 included forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1)
and the FEV1/FVC ratio, which in most cases were mea-
sured by whole-body plethysmography (Jaeger MasterLab
Germany, Vmax Autobox, VIASYS Healthcare Inc.,
SensorMedics, California, USA). The values published
by the European Respiratory Society were used as reference
values [23]. A significant obstructive ventilatory impairment
was assumed to be present when the FEV1/FVC ratio
was <0.7 [24].
To test NSBHR with acetyl-β-methylcholine chloride
inhalation, Mefar dosimeters (Mefar MB3, Brescia, Italy)
were used. The results were expressed as the cumulative
doses required to provoke an FEV1 reduction of 20%
(PD20) graded according to the ATS scheme which was
slightly modified [25]. If the FEV1 was <70% of the pre-
dicted value, the test was not performed, and the revers-
ibility was checked by inhaling two puffs of salbutamol
(200 μg DA). Generally we defined NSBHR in the partici-
pants as having a fall in FEV1 of >20% by inhaling ≤2 mg
methacholine or having an increase in FEV1 of >10% after
inhalation of salbutamol.
To confirm respiratory tract sensitisation to diisocyanates
at T0, 31 of the 49 patients underwent a specific-inhalation
challenge in the Thurgau-Schaffhausen Alpine Clinic
in Davos according to a standardised protocol with the
relevant diisocyanates or isocyanate-containing products.
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20% could be demonstrated and if the dose response
curve showed a typically shaped immediate, late or dual
reaction [26].
To compare the results between the beginning and the
end of the follow-up examinations, only complete data
sets were accounted for; i.e., those of dropouts were
discarded. In order to check for prognostic factors we
also stratified participants according to their FEV1%
predicted, FEV1/FVC ratio at T0 and a change in FEV1%
predicted between T0 and T1.
Continuous variables are reported as a mean ± standard
deviation (SD) or median plus interquartile range (IQR)
when non-normally distributed. Statistical tests applied
were the Kolmogorov-Smirnov, the McNemar’s-, paired
t-, Sign-, Wilcoxons-Mann–Whitney- and the chi-squared
test. After performing univariate analyses, a logistic re-
gression analysis with staggered inclusion of co-variates
was performed to evaluate the effects of different variables
on dependent variables such as “persistent asthma symp-
toms” and “persistent bronchial hyperresponsiveness at
follow-up”. In the “a priori” models we selected some vari-
ables (age at diagnosis, total exposure time, exposure time
with symptoms) that were already shown to be associated
with asthma outcome [16]. In the “a posteriori” models we
included co-variates in whom univariate analyses showed
significant or borderline associations with the dependent
variables. Statistical analyses were performed by applying
the PSPP software package [27]. To calculate mean
values ± SD, median values and IQRs, Microsoft Excel
for Mac Version 14.3.9 software was used. A p < 0.05 was
considered to be statistically significant.
Results
Forty-nine patients (47 males, 2 females; mean age, 38 ± 13
years) were considered for inclusion into the study. These
patients represented all individuals who claimed compensa-
tion between 1993 and 1995 and for whom the diagnosis of
DIA could be established. Most of the study participants
were car spray painters, industrial spray painters, furni-
ture spray painters, carpenters and cabinet makers (49%),
followed by polyurethane foam casters and moulders
(37%) and other craftsmen (14%).
We observed that 86% of the subjects were no longer
being exposed to isocyanates when the diagnosis of OA
was made (T0). They had ended their exposure on average
one month before the investigation (range, 30 months
before to 7 months thereafter) because Suva declared 44
of them unsuitable for further isocyanate-related occupa-
tional activities (declaration of “unsuitability” [DOU]) [28].
Five patients could not be declared unsuitable because
three of them were self-employed persons, one received
an invalidity pension for a non-occupational disease
and one was affected from DIA very early during hisapprenticeship so that a DOU was not indicated. In
practice, the DOU resulted in nearly all of the patients
changing their workplace or their employer. The median
overall isocyanate exposure time of the whole cohort was
57 months (IQR 108 months), and the median symptom-
atic exposure time was 16 months (IQR 30 months).
After a mean interval of 12 years (range, 11.0–13.0
years), 35 of the 49 patients could be contacted and agreed
to be re-examined, corresponding to a re-examination rate
of 71.4%. Figure 1 summarizes the flow of patients and the
reasons for non-follow up. Twenty-two subjects (63%)
were still working. One of them remained at the original
workplace as a car spray painter but had switched to non-
isocyanate-containing varnishes, 4 (11%) had relocated to
completely isocyanate-free workplaces within the same
company, and 17 (49%) had changed their job as well as
their employer to avoid further isocyanate exposure.
Thirteen subjects were no longer occupationally active,
7 due to premature or regular retirement; 3 were on
social welfare, 2 were unemployed and one was on long-
term sick leave unrelated to DIA.
The characteristics of the 35 participating subjects and
the 14 dropouts are shown in Table 1. Except for the
lower PD20 at T0 for those that were not re-examined
later, the other variables did not significantly differ from
those of the individuals that were re-investigated for this
study.
Table 2 represents the changes in symptoms, asthma
therapy, health status and overall satisfaction for those
participants for whom follow-up data was available. It
shows a significant decline in the frequency of symptoms,
use of asthma medication - especially inhaled corticoste-
roids - and an increase in subjective health status and
overall satisfaction.
Table 3 summarizes the results of pulmonary function
tests for the 35 subjects who were re-examined for this
study. Lung function values were slightly lower at T1
compared to T0 reaching the level of significance only
for FEV% predicted and for the FEV1/FVC ratio. 34 of
35 participants were tested for NSBHR either by metha-
choline challenge or by bronchodilatation with salbuta-
mol. While 23 subjects (68%) were positive at the time of
diagnosis their number decreased to 17 (50%) at T1, a
result that did not reach statistical significance (p = 0.22).
When focussing on the 26 participants whose tests were
done by the same method on both occasions (22 by
methacholine and 4 by bronchodilatation) the number of
positive results again dropped from 18 to 15 (14 metha-
choline and 4 bronchodilatation tests at T0; 14 methacho-
line and 1 bronchodilatation test at T1) a decline that
again did not reach statistical significance. The same was
true for those 22 patients who underwent methacholine
challenge tests (median of PD20 0.95 mg (IQR 1.68 mg) at





4 died during follow up*
2 moved abroad
3 unable to contact
1 severe illness
4 refusal 
47 males, 2 females
22 underwent methacholine test, 
27 underwent bronchodilator test
33 males, 2 females
22 underwent methacholine test, 
12 underwent bronchodilator test
1 refused testing for bronchial  
hyperresponsiveness
14 dropouts
Figure 1 Flow-chart of recruited patients. Legend: T0 = time of diagnosis, T1 = time of re-evaluation. *Reasons for death (coronary heart disease
(n = 1), aspiration pneumonia (n = 1), unknown (n = 2)).
Table 1 Baseline characteristics of participants and






Age at diagnosis 39 ± 13 36 ± 13 0.53
Sex (males) 33 (94%) 14 (100%) 1.0
FVC% predicted 102 ± 17 97 ± 13 0.37
FEV1% predicted 91 ± 16 90 ± 16 0.89
FEV1/FVC 75 ± 9 74 ± 10 0.50
PD20 (mg) 0.95 (1.7) 0.30 (0.5) 0.03
NSBHR positivity 23 (68%) 11 (92%) 0.13
Total exposure time (months) 51 (104) 74 (89) 0.77
Time with symptoms (months) 12 (26) 24 (31) 0.38
Smokers 10 (29%) 6 (43%) 0.5
Pack-years* 25 (24) 13 (14) 0.16
Upper airway symptoms 28 (80%) 11 (79) 1.0
Asthma symptoms 34 (97%) 14 (100) 1.0
Asthma medication 31 (91%) 8 (89) 1.0
Legend: FVC = forced expiratory vital capacity. FEV1 = forced expiratory volume
in 1 second. NSBHR = nonspecific bronchial hyperreactivity. PD20 = provocative
dose of methacholine producing a fall in FEV1 of 20%. *Pack-years for smokers
and ex-smokers added. Data is presented as mean ± SD, median and interquartile
range (IQR) or number (%).
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to lung function at T0 and lung function loss during
follow-up. Age, FEV1/FVC, smoking variables and expos-
ure data in those individuals with FEV1 < 80% predicted
at T0 were not different from those with better lung
function. The same was true for those with ≥15% loss of
FEV1% predicted between T0 and T1. Individuals with a
FEV1/FVC ratio <0.7 at T0 had a lower FEV1% pre-
dicted and a higher tobacco consumption than those
with higher FEV1/FVC ratio.Table 2 Change in symptoms, therapy and visual analogue
scale (VAS) ratings between T0 and T1 (n = 35)
T0 T1 p-value
Upper airway symptoms 28 (80%) 9 (26%) <0.001
Asthma symptoms 34 (97%) 20 (57%) <0.001
Use of asthma medication* 31 (91%) 19 (56%) 0.002
Short acting beta2 agonists 19 (56%) 13 (38%) 0.18
Long acting beta2 agonists 10 (29%) 10 (29%) 1.0
Inhalable corticosteroids 26 (76%) 10 (29%) <0.001
Smokers 10 (29 %) 14 (40%) 0.05
VAS (cm) health status 1.2 (2.9) 8.0 (4.0) <0.001
VAS (cm) overall satisfaction 2.1 (6.1) 8.3 (3.4) <0.001
Legend: Upper airway symptoms (conjunctivitis, rhinitis, hoarseness,
pharyngeal irritant sensations); asthma symptoms (irritation, wheezing, chronic
cough, chest tightness and dyspnoea); VAS = visual analogue scale. Data is
presented as mean ± SD, median and interquartile range (IQR) or number (%).
*n = 34.
Table 3 Results of lung function and hyperreactivity
testing at T0 and T1
T0 T1 p-value
FVC% predicted 102 ± 17 96 ± 17 0.04
FEV1% predicted 91 ± 16 87 ± 18 0.06
FEV1/FVC 76 ± 9 73 ± 8 0.01
PD20 (mg) 0.95 (1.7) 0.70 (1.7) 0.81
Legend: FVC = forced vital capacity. FEV1 = forced expiratory volume in one
second. PD20 = provocative dose of methacholine causing a 20% fall in FEV1.
NSBHR = nonspecific bronchial hyperreactivity.
Data is presented as mean ± SD or median and interquartile range (IQR).
Table 5 Baseline characteristics of patients according to






Age (years) 37 ± 14 42 ± 9 0.34
FEV1% predicted 95 ± 13 83 ± 20 <0.001
Current smoking 7 (28%) 3 (30%) 1.00
Pack years* 5 (12) 20 (20) <0.001
Total exposure time (months) 44 (80) 145 (143) 0.16
Symptomatic exposure
time (months)
11 (15) 19 (33) 0.31
Legend: FVC = forced expiratory vital capacity. FEV1 = forced expiratory volume
in 1 second. *Pack-years for smokers and ex-smokers added.
Data is presented as mean ± SD, median and interquartile range (IQR) or
number (%).
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analysis can be seen in Table 7. In the “a priori” models
age was associated with persistent asthma symptoms at
follow-up (p = 0.02) and persistent NSBHR was associated
with total exposure time (p = 0.04). In the predictive “a
posteriori” model the degree of airflow limitation at diag-
nosis was associated with persistent asthma symptoms
at T1 (p = 0.05). Asthma medication (p < 0.001) and age
(p = 0.06) at T1 were associated with asthma symptoms
both at follow up.
Discussion
The aim of our 12-year follow-up study was to investigate
the long-term outcome of patients with DIA, to check for
possible prognostic factors and to compare these results
obtained in Switzerland with those reported in the litera-
ture, primarily of the two previously cited larger cohorts
of patients with DIA [19,20]. We found that at a mean of
12 years after removal from exposure to the offending
diisocyanates, the majority of the patients reported fewer
respiratory symptoms, decreased asthma medication use
and a better self-reported overall health status while lung
function values at follow up were slightly lower compared
to normal.
At T1, 14 of the initially evaluated 49 patients at T0
could not be retraced (dropout rate 28.6%). The 35Table 4 Baseline characteristics of patients according to
their FEV1 at T0
FEV1 ≥ 80%
pred. (n = 28)
FEV1 < 80%
pred. (n = 7)
p-value
Age 38 ± 13 42 ± 10 0.44
FEV1/FVC 77 ± 8 72 ± 11 0.20
Current smoking 8 (29%) 2 (29%) 1.0
Pack years* 7 (15) 20 (13) 0.37
Total exposure time (months) 51 (99) 53 (129) 0.68
Symptomatic exposure
time (months)
13 (34) 8 (14) 0.22
Legend: FVC = forced expiratory vital capacity. FEV1 = forced expiratory volume
in 1 second. *Pack-years for smokers and ex-smokers added.
Data is presented as mean ± SD, median and interquartile range (IQR) or
number (%).patients who could be followed until T1 represent a small
sample size, a fact that weakened the informative value of
our results. Piirilä (8% non-responders in their first phase
questionnaire survey) and, particularly, Padoan and co-
workers (no non-responders) did clearly better in this re-
gard. Nevertheless, the 71.4% who re-participated in our
study were within the range of other but shorter follow-up
studies [15,29-32]. When analysing our data retrospect-
ively, dropouts were having a more pronounced bronchial
hyperreactivity (p = 0.03) at diagnosis compared to partici-
pants. With respect to all the other variables such as
smoking status, job groups (data not shown), age, the
presence of airway symptoms, the level of FVC and
FEV1% predicted as well as the FEV1/FVC ratio or the
overall exposure time period, we could not find any
significant differences between study participants and
dropouts. Thus we believe that the participants repre-
sent fairly well the whole study group, a fact that might
outweigh to some extent its small sample size.
Based on the average number of the Swiss working
population of 4 millions during 1993 – 1995 (SwissTable 6 Baseline characteristics of patients according to
their FEV1 loss between T0 and T1
FEV1 loss
< 15% (n = 28)
FEV1 loss
≥15% (n = 7)
p-value
Age 37 ± 13 45 ± 10 0.11
FEV1% pred.at T0 90 ± 17 98 ± 13 0.25
FEV1/FVC at T0 77 ± 9 72 ± 7 0.25
Current smoking 8 (29%) 2 (29%) 1.0
Pack years* 11 (17) 11 (17) 0.42
Total exposure time (months) 46 (91) 62 (169) 0.32
Symptomatic exposure
time (months)
11 (19) 19 (49) 0.40
Legend: FVC = forced expiratory vital capacity. FEV1 = forced expiratory volume
in 1 second. *Pack-years for smokers and ex-smokers added.
Data is presented as mean ± SD, median and interquartile range (IQR) or
number (%).
Table 7 Multivariate logistic regression analysis of predictors for persistent asthma at follow-up
“A priori” “A posteriori”
Predictive Descriptive
Model 1 Model 2 Model 3 Model 4









Age at T0 0.08 (p = 0.02) 0.03 (p = 0.35) 0.04 (p = 0.27)
Age at T1 0.09 (p = 0.06)
Total exposure time −0.02 (p = 0.04)
Symptomatic exposure time 0.01 (p = 0.37) 0.03 (p = 0.10)
Upper airway symptoms at T0 −1.91 (p = 0.12)
Upper airway symptoms at T1 1.36 (p = 0.29)
FEV1/FVC at T0 −0.11 (p = 0.05)
Asthma medication at T1 2.85 (p < 0.001)
Intercept −2.90 −0.32 9.01 −5.98
R2 0.22 0.28 0.39 0.55
Legend: FVC = forced expiratory vital capacity, FEV1 = forced expiratory volume in 1 second. NSBHBR = non specific bronchial hyperreactivity. R2 = Nagelkerke
R Square. Data are presented as B-coefficient (p-value).
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to a yearly incidence rate of 4.1 cases/million which is
somewhat higher than in France by ONAP indicating
3.5 cases/million [33] but considerably lower than the
10.8 cases/million reported by the PROPULSE program in
Québec, Canada [34]. To note that both these sentinel
programs became active during the 1990ies i.e. during the
same time period when we were following-up our patients
and – more important - that we report on legally compen-
sated cases only unlike those published from Québec and
from France.
Removing an asthmatic worker from the offending
agent leads to an improvement in asthma severity, a fact
that was confirmed by Rachiotis and co-workers [16]
when doing a systematic literature review and meta-
analysis on the outcome of occupational asthma after
cessation of exposure. The authors found a pooled rate
of symptomatic recovery of 32% (95% CI 26%–38%).
This finding is in agreement with the results of a recent
review issued by Baur and co-workers [21], who found
that, on average, 33.7% of patients (95% CI 23.6%–45.6%)
no longer exhibited symptoms after complete cessation of
exposure to the offending agent. These results indicate
that usually more than 50% of the subjects remain symp-
tomatic, which is in line with our figures showing that
57% of the patients continued to complain of asthma
symptoms at follow up, a finding that is slightly better
than that observed in the studies by Piirilä and Padoan
[19,20], in which more than two thirds of the patients
remained asthmatic.
In our study most of the patients were still on anti-
asthmatic medication at follow-up; more than half of themwere taking it on a regular basis, whereas 10 were still
inhaling corticosteroids. These results are comparable to
those of both the Piirilä and the Padoan studies, in which
66% and 60%, respectively, of the patients required some
form of anti-asthmatic treatment at the end of their
follow-up, approximately half of them again on a regular
basis in the Piirilä study [19]. According to an extended
literature survey that was conducted by the Agency for
Healthcare Research and Quality (AHRQ), the proportion
of OA patients who require medication after cessation of
exposure ranges from 17% to 100%, depending to a great
extent on the characteristics of the cohort and on ex-
posure. Furthermore, the AHRQ data suggest that 4
years after removal of the offending low-molecular-
weight agent, approximately half of the patients are
still under treatment [35], which is in line with what
we have observed.
In contrast to the Piirilä and the Padoan studies, we
asked the patients to assess their individual state of
health as well as their overall satisfaction using a VAS.
To the best of our knowledge, these factors have not
been addressed in another comparable long-term DIA
study. On a group basis, we observed a statistically sig-
nificant increase in self-reported health status and
overall satisfaction between T0 and T1, results that were
comparable to those of the Karvala study, in which the
overall quality of life parameter in patients with occupa-
tional asthma to moulds was reported to be between 6.5
and 7.4 [36]. When we stratified our VAS ratings according
to the presence or the absence of symptoms, we observed
that those without asthma symptoms at follow-up were
reporting even better satisfaction than those with persistent
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majority of “normal persons” would not set their VAS
mark precisely on 10 but rather somewhat lower, our
results for the group without symptoms at follow-up
do not likely differ from what could be expected from
healthy people.
We admit that VAS results have to be interpreted with
caution. First of all one can argue that patients who could
not be followed up – dropouts - would have been more
seriously diseased judging their quality of life significantly
lower than the participants thus biasing the observed
results in a too optimistic direction. However we think
that this hypothesis is not very probable, as – with the
exception of PD20 – there were no significantly different
baseline characteristics between participants and dropouts
(Table 1). Secondly there is no doubt that any self-
assessment, especially if done retrospectively, is subjective
and can thus be biased. However we had no indication for
subjects to under or over report their state of health at
T0 or T1 except that – in theory - some over-reporting
could have been expected because the interviewers were
physicians who were employed by Suva the compensating
body. Such a tendency could have biased the VAS mark-
ings towards a lower level at T0 as well as at T1 thus not
decisively change the absolute amount of improvement
we observed.
Complete cessation of exposure to the offending agent
improves symptoms as well as lung function [37] but is
associated with worse socioeconomic outcomes [15,35,38],
thereby increasing anxiety and depressive symptoms
[31,39-41] that, in turn, have a negative impact on asthma
outcome. When examining the data on socioeconomic
factors at T1, we found that those 13 patients who were
not working lost on average 19.2% of their income, 7 of
them after retiring regularly or prematurely, incurring an
income reduction either way. Those who were still eco-
nomically active (22 of 35) had a salary increase of 13.7%
(after retraining) or a slight loss of 6% (without retraining)
[42]. To look at the impact of both symptoms and income
on overall satisfaction at the end of the follow-up, we
found that persisting asthmatic symptoms entailed a
clearly lower VAS ranking than the loss of income. It is
obvious that the latter does not reflect all aspects of
possible socioeconomic problems. Nevertheless, we think
that once financial problems have been managed and an
alternative job is found, to the patients’ satisfaction,
psychological distress will be alleviated, resulting in better
tolerability of the remaining symptoms, as observed by
Piirilä and Keskinen [19,43].
Lung function in the participants was lower than those
reported in the Piirilä and the Padoan studies (99.6%
and 98.8% predicted respectively) [19,20]. According to
the literature, the lungs are not completely developed by
late adolescence, with lung function values not plateauinguntil early in the third decade of life [44]. Two of our 35
subjects were only 17 and 18 years old at diagnosis, a fact
that could explain the slight reduction in the average lung
volumes at the beginning of the study but not an isolated
decrease in FEV1.
The decreases in FVC% predicted as well as in the
FEV1/FVC ratio between T0 and T1 were small but
significant, whereas the FEV1% predicted changed only
insignificantly even though the number of patients with
overt airflow limitation remained numerically constant
(n = 10). These results are again consistent with those of
Piirilä, Padoan and others, indicating slight but overt lung
function deterioration during follow-up.
When specifically looking at the observed small FEV1/
FVC decrease, which is based on a fixed lower limit of
0.7 instead of using calculated limits of normal, as has
been recommended earlier [45,46], we believe that this
decrease might be attributed, at least in part, to the
physiological loss of elastic recoil by ageing. This argu-
ment holds true only if one assumes that any substantial
recovery of the lung volume of our subjects occurred
during the approximately one-month time period between
the cessation of exposure and the examination at T0,
outweighing the observed volume decrease. In any case
it is questionable whether the observed small lung func-
tion decreases are clinically relevant. Another possible
explanation for the decrease in lung volumes might be
persisting diisocyanate exposure. However, this can be
largely ruled out because 86% of the subjects had been
removed from any further contact by the time of T0,
although 9 persons reported having had sporadic and
unintended diisocyanate exposures during the follow-up
period.
Overall there was a trend for a decrease in the number
of individuals with NSBHR having either a positive chal-
lenge test to methacholine or a significant reversibility
after inhalation of a short acting bronchodilatator. How-
ever when considering PD20 in individuals who underwent
methacholine testing at the beginning and at the end of
the follow up period, no significant change could be ob-
served. It is well known that the duration of symptomatic
exposure and the level of NSBHR are risk factors for
persistent NSBHR and that some individuals keep their
NSBHR despite complete removal from the exposing
allergen in the workplace [16,21,47]. We believe that
two factors might explain our result: Firstly our NSBHR
test pairs are incomplete, potentially biasing the result in
favour of those subjects doing worse; and secondly we
observed an overall increase of active smokers during
follow-up (Table 2), which by itself might be a risk factor
for NSBHR [48].
When analysing our participants according to their
lung function at T0 or its change during follow up (Tables 4,
5 and 6) we did not find any significant differences
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and non affected individuals, FEV1 and tobacco consump-
tion for the patients with a FEV1/FVC ratio <0.7 (Table 5)
excluded, though some of the criteria we looked at are
known prognostic factors of OA [9,16,21].
The presence of airflow limitation is a known prognostic
factor for asthma, COPD and other (respiratory) diseases.
When we compared the patients having an FEV1/FVC
ratio <0.7 with those who were non-obstructive at T0
(Table 5) we found the former to have started with a
significantly lower FEV1% predicted and to have had a
significantly higher tobacco consumption while the
other parameters did not differ between the two groups
(Table 5) [16,21]. Again these results are very well com-
parable with what has been published in the literature ex-
cept for tobacco consumption that is not an accepted risk
factor for DIA [6,9]. Nevertheless we assume that in some
of our patients airflow limitation at T0 was due to both
isocyanate as well as tobacco exposure, the latter playing
an explicit role as aggravating factor as it is known that
smoking adversely affects asthma outcome due to altered
airway inflammation and corticosteroid insensitivity con-
tributing therefore to a high rate of symptom persistence
and lung function loss at follow-up [49]. Further it is
possible that some of our subjects started their iso-
cyanate exposure with a pre-existing airflow limitation,
a hypothesis we cannot prove because we do not dispose
of any medical data for the time when they started their
isocyanate exposure.
When we further stratified our cohort according to
the FEV1 loss that was observed between T0 and T1
(Table 6) we largely obtained the same results: The
“marked decliners” (FEV1 loss ≥15% predicted) tended
to be older, to have a lower FEV1% predicted at T0 and a
longer total diisocyanate as well as a symptomatic expos-
ure time.
Finally we tried to identify factors that were associated
with the long-term outcome such as persistent asthmatic
symptoms and NSBHR by performing a multivariate lo-
gistic regression analysis. Several studies did report that
duration of (symptomatic) exposure and age at diagnosis
are associated with adverse outcomes of occupational
and non-occupational asthma [9,16,21]. This is what we
could confirm in the “a priori model” as age and exposure
time were associated with DIA outcomes. In the “a poster-
iori model” the FEV1/FVC ratio was the factor that best
predicted persistent asthma symptoms at follow-up. Fi-
nally age and asthma medication at follow-up were the
co-variates that were associated with persistent asthma
symptoms at follow-up. To note that age might be
linked to the length of exposure, two variables that have
not been clearly disentangled until now [9]. However in
our sample age and total exposure time did not correlate
at all (Pearson Correlation Coefficient = 0.11, p = 0.47)while total exposure time showed only a moderate correl-
ation with symptomatic exposure time (Pearson Correlation
Coefficient = 0.53, p < 0.001). Rachiotis and co-workers
found - based on 2 studies only – older patients to be
more likely to completely recover from NSBHR while 5
out of 6 other cited studies reported shorter durations
of exposure to be associated with a better outcome in
terms of physiological recovery respectively NSBHR.
Rachiotis’ result is supported – at least in tendency - by
Baur and colleagues [21] who pointed to the fact that the
data from the literature they based their report upon were
mostly not significant. To conclude there is no firmly
established association between NSBHR and independent
variables such as age and duration of exposure while
NSBHR positivity at the time of diagnosis is a negative
prognostic factor [9,21].
The finding of an association between the FEV1/FVC
ratio at T0 and the persistence of asthma symptoms at T1
is supported by the review of Maestrelli and co-workers
who stated that impaired lung function at diagnosis had a
negative role on the outcome of OA though they report
only isolated data on FEV1 and FVC but not on their
ratio.
In retrospect, we recognised that medical examinations
dating back to the start of exposure would have been very
helpful enabling us to look for individuals at risk when
further exposed to noxious substances at their workplaces.
As part of preventive measures, we would recommend
reasonable medical pre-employment or at least surveillance
programs to be introduced not only for all isocyanate-
exposed workers but for all persons at risk to develop oc-
cupational asthma [1,21,50,51].
Conclusion
In conclusion, we found that more than 50% of our 35
subjects suffering from DIA reported to remain symptom-
atic, had worse lung function and were in need of therapy
for asthma after an exposure-free follow-up period of 12
years. In contrast, the patients’ self-assessment of their
health and overall satisfaction increased considerably
during the observation period, which is primarily a conse-
quence of becoming symptom free and having satisfactor-
ily resolved their socioeconomic problems. Persistence of
asthma symptoms and NSBHR was associated with age,
exposure time and lung function at the time of diagnosis
(T0). Our results suggest that surveillance programs as
well as information on occupational risks for asthma and
early symptoms recognition should be offered to the
workforce thereby not excluding older and experienced
workers as they are still at risk for DIA the latter being
characterized by worse outcomes. Finally workers and
especially patients with diagnosed occupational asthma
should receive counselling on smoking cessation as con-
tinuous smoking may adversely affect asthma outcomes.
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